SPC437

Etranacogene dezaparvovec (an adeno-associated viral vector containing a codon-optimized Padua derivative of human coagulation factor IX gene for the treatment of hemophilia B)

  • Status:
    Umsókn
  • Application date:
    25.7.2023
  • Application published:
    15.8.2023
  • Max expiry date:
    14.9.2034
  • Medicine name:
    Hemgenix
  • Medicine for children:
    No

Timeline

Today
25.7.2023Application
15.8.2023Publication
14.9.2034Expires

Marketing license

  • IS authorization number:
    EU/1/22/1715
  • Date:
    22.3.2023
  • Foreign authorization number:
    EU/1/22/1715/001
  • Date:
    20.2.2023

Owner

  • Name:
    uniQure biopharma B.V.
  • Address:
    Paasheuvelweg 25a, 1105 BP Amsterdam NL

Agent

  • Name:
    Árnason Faktor ehf.
  • Address:
    Guðríðarstíg 2-4, 113 Reykjavík

Patent

Upload documents